Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A

NASDAQ:KNSA  
13.39
+1.70 (+14.54%)
Products

Kiniksa Pharmaceuticals Announces Global License Agreement With Genentech For Vixarelimab

Published: 08/03/2022 13:28 GMT
Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A (KNSA) - Kiniksa Pharmaceuticals Announces Global License Agreement With Genentech for Vixarelimab.
Kiniksa Pharmaceuticals Ltd - Kiniksa to Receive $100 Million in Upfront and Near-term Payments.
Kiniksa Pharmaceuticals Ltd - Kiniksa is Eligible to Receive Development and Commercial Milestones As Well As Royalties on Net Sales.
Kiniksa Pharmaceuticals Ltd - Global License Includes Development and Commercialization Rights to Vixarelimab.
Kiniksa Pharmaceuticals Ltd - Under Terms of Global License Agreement, Kiniksa Will Receive $100 Million in Upfront and Near-term Payments.
Kiniksa Pharmaceuticals Ltd - Completed Screening Patients for Phase 2b Clinical Trial of Vixarelimab in Prurigo Nodularis.
Kiniksa Pharmaceuticals - is Eligible to Receive Up to About $600 Million in Certain Clinical, Regulatory, Sales-based Milestones.
Kiniksa Pharmaceuticals Ltd - Plans to Complete Trial But Will No Longer Disclose Data in Second Half of 2022.